Immuron (IMRN) Long-Term Deferred Tax (2017 - 2023)
Immuron (IMRN) recorded quarterly Long-Term Deferred Tax of $18660.6 in Q2 2023, up 195.75% quarter-over-quarter from $6309.6 in Q2 2022, and up 195.75% on a YoY basis from $6309.6 in Q2 2022.
Immuron (IMRN) Long-Term Deferred Tax (2017 - 2023) Analysis & Trends
Immuron's Long-Term Deferred Tax history runs 4 years deep, the most recent figure standing at $18660.6 for Q2 2023.
- In Q2 2023, Long-Term Deferred Tax rose 195.75% year-over-year to $18660.6; the TTM figure through Jun 2023 stood at $18660.6 (up 195.75% YoY), while the FY2023 annual figure was $18660.6, up 195.75% from the prior year.
- Long-Term Deferred Tax was $18660.6 for Q2 2023 at Immuron, up from $6309.6 in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $18660.6 in Q2 2023 to a low of $6309.6 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Immuron | 921.61 Mn | 921.58 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 18,660.62 |
| Jun 30, 2022 | 6,309.61 |
| Jun 30, 2018 | 7.35 Mn |
| Jun 30, 2017 | 6.23 Mn |